JPH08208527A - Particular barium sulfate preparation for internal use - Google Patents
Particular barium sulfate preparation for internal useInfo
- Publication number
- JPH08208527A JPH08208527A JP7016741A JP1674195A JPH08208527A JP H08208527 A JPH08208527 A JP H08208527A JP 7016741 A JP7016741 A JP 7016741A JP 1674195 A JP1674195 A JP 1674195A JP H08208527 A JPH08208527 A JP H08208527A
- Authority
- JP
- Japan
- Prior art keywords
- barium sulfate
- digestive tract
- preparation
- binder
- ethylcellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、Ｘ線撮影による消化管
検査の為の造影剤として服用される硫酸バリウム粒状製
剤に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a barium sulfate granular preparation to be taken as a contrast agent for examination of the digestive tract by radiography.
【０００２】[0002]
【従来の技術】従来、消化管の検査方法として硫酸バリ
ウム懸濁液を被検者に飲用させＸ線撮影を行なう方法が
広く利用されている。2. Description of the Related Art Conventionally, as a method for examining the digestive tract, a method in which a subject is allowed to drink a suspension of barium sulfate and X-ray photography is widely used.
【０００３】ところが、最近単に消化管を撮影するだけ
でなく消化管の機能の検査、例えば胃や腸の蠕動運動能
力の検査等が必要な場合がある。However, recently, in addition to simply taking a picture of the digestive tract, it may be necessary to examine the function of the digestive tract, for example, the examination of the peristaltic movement ability of the stomach and intestines.
【０００４】[0004]
【発明が解決しようとする課題】このような消化管機能
の検査方法としては、従来は適当な手段がなかった。そ
こで、従来の消化管Ｘ線造影剤の硫酸バリウムを少量用
いて、経時的移動を検査することが試みられた。しかし
ながら、従来の硫酸バリウムは服用後に速やかに沈降凝
集してしまうので消化管の機能診断用には不適当であっ
た。As a method for examining such digestive tract function, there has been no suitable means in the past. Therefore, it has been attempted to examine the migration over time using a small amount of barium sulfate, which is a conventional gastrointestinal X-ray contrast agent. However, conventional barium sulfate is not suitable for diagnosing digestive tract function because it rapidly precipitates and aggregates after administration.
【０００５】本発明は、服用後もそのままの形状を保っ
て、消化管の運動を妨げることなく移動し、消化管の機
能診断に利用できる造影剤を提供することを目的とする
ものである。An object of the present invention is to provide a contrast medium which can be used for diagnosing the function of the digestive tract by keeping its shape even after taking, moving without disturbing the movement of the digestive tract.
【０００６】[0006]
【課題を解決するための手段】本発明者らは上記目的を
達成するべく鋭意検討を進めた結果、エチルセルロース
が毒性のない結合剤として硫酸バリウム粒子をよく結着
して消化管内で粒状状態を維持することができるもので
あることを見出し、この知見に基づいて本発明を完成す
るに到った。Means for Solving the Problems As a result of intensive studies to achieve the above object, the present inventors have found that ethyl cellulose binds barium sulfate particles well as a non-toxic binder to form a granular state in the digestive tract. They have found that they can be maintained, and have completed the present invention based on this finding.
【０００７】すなわち、本発明は結合剤またはコーティ
ング剤としてエチルセルロースが使用されている硫酸バ
リウム粒状製剤に関するものである。That is, the present invention relates to a barium sulfate granular preparation in which ethyl cellulose is used as a binder or a coating agent.
【０００８】この硫酸バリウム粒状製剤は、エチルセル
ロースが硫酸バリウム粒子の結合剤として使用されてい
る態様と、他の結合剤で結合された硫酸バリウム粒のコ
ーティング剤として使用されている態様と、結合剤及び
コーティング剤の両方に使用されている態様がある。This barium sulfate granular preparation has a mode in which ethyl cellulose is used as a binder for barium sulfate particles, a mode in which it is used as a coating agent for barium sulfate particles bonded with another binder, and a binder. And a coating agent.
【０００９】形状としては顆粒状のほか球状、三角形、
四角形、柱状、短管状等任意の形状とすることができ
る。形状を変えて逐時投与することによって消化管運動
の経時変化を判断しやすくなる利点が得られる。As for the shape, in addition to granular shape, spherical shape, triangular shape,
The shape can be any shape such as a quadrangle, a column, and a short tube. The advantage of making it easier to determine the time course of gastrointestinal motility is obtained by changing the shape and administering the compounds one by one.
【００１０】硫酸バリウム粒の粒径としては平均粒径で
５０μｍ〜８ｍｍ程度、好ましくは５００μｍ〜３ｍｍ
程度が適当である。The average particle size of the barium sulfate particles is about 50 μm to 8 mm, preferably 500 μm to 3 mm.
The degree is appropriate.
【００１１】エチルセルロースはエタノール可溶性でか
つ水に難、不溶性のものであり、エトキシル化率では４
３〜５０％程度のものである。Ethyl cellulose is soluble in ethanol, difficult and insoluble in water, and has an ethoxylation rate of 4%.
It is about 3 to 50%.
【００１２】エチルセルロースを結合剤として使用する
場合には、その配合量は粒状製剤の２〜４０重量％程
度、好ましくは５〜３０重量％程度、特に好ましくは１
０〜２０重量％程度が適当である。一方、コーティング
剤として使用する場合にも同様である。When ethyl cellulose is used as a binder, its content is about 2 to 40% by weight, preferably about 5 to 30% by weight, and particularly preferably 1% by weight of the granular preparation.
About 0 to 20% by weight is suitable. On the other hand, the same applies when used as a coating agent.
【００１３】エチルセルロースをコーティング剤として
使用する場合には他の結合剤を硫酸バリウム粒子を粒状
化するために使用することができる。この場合、他の結
合剤としては、ポリビニルピロリドン、ヒドロキシプロ
ピルセルロース、ヒドロキシプロピルメチルセルロー
ス、ヒドロキシプロピルメチルセルロースフタレート等
があり、その配合量は硫酸バリウム１００重量部に対し
乾燥重量で１．０〜４重量部程度が適当である。Other binders can be used to granulate the barium sulfate particles when ethyl cellulose is used as the coating agent. In this case, other binders include polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, etc., and the compounding amount thereof is 1.0 to 4 parts by weight on a dry weight basis with respect to 100 parts by weight of barium sulfate. The degree is appropriate.
【００１４】本発明の粒状製剤の製造方法としては、エ
チルセルロースエタノール溶液を硫酸バリウム粉末に加
えて混練し、造粒あるいは打錠し、乾燥すればよい。こ
の混練、造粒あるいは打錠、乾燥には公知の混合型造粒
機、打錠機などを使用することができる。As a method for producing the granular preparation of the present invention, an ethyl cellulose ethanol solution may be added to barium sulfate powder, kneaded, granulated or tableted, and dried. For this kneading, granulation or tableting, and drying, a known mixing type granulator, tableting machine or the like can be used.
【００１５】本発明の硫酸バリウム粒状製剤はＸ線撮影
あるいは投影によって消化管検査を行なう直前に適当量
の水を用いて被検者に飲用させればよい。飲用量は消化
管機能検査を行なう場合には１〜１０ｇ程度、特に２〜
６ｇ程度が適当である。The barium sulfate granular preparation of the present invention may be given to a subject by using an appropriate amount of water immediately before the examination of the digestive tract by X-ray photography or projection. Drinking dose is about 1 to 10 g, especially 2 to 1 when performing gastrointestinal function test.
About 6g is suitable.
【００１６】[0016]
【作用】本発明の硫酸バリウム顆粒製剤は被検者が飲用
後も消化管内で凝集沈降が起こらず顆粒状態が維持され
て流動性が高い。その結果、消化管の蠕動運動によって
流動し、消化管の運動機能検査を行なうことができる。The barium sulfate granule preparation of the present invention has high fluidity because the granule state is maintained in the digestive tract without agglomeration and sedimentation even after the subject drinks it. As a result, the peristaltic movement of the digestive tract causes fluidization, so that the motor function of the digestive tract can be tested.
【００１７】[0017]
【実施例】硫酸バリウム（日本薬局方）８８０重量部に
医薬品添加物規格のエチルセルロース（「信越エチルセ
ルロース」信越化学製）１２０重量部を加えて混練し、
造粒、乾燥して平均粒径１．５ｍｍの顆粒品を調製し
た。[Examples] To 880 parts by weight of barium sulfate (Japanese Pharmacopoeia), 120 parts by weight of ethyl cellulose ("Shin-Etsu ethyl cellulose" manufactured by Shin-Etsu Chemical Co., Ltd.), which is a standard for pharmaceutical additives, was added and kneaded.
Granulation and drying were performed to prepare granules having an average particle size of 1.5 mm.
【００１８】この顆粒剤２ｇを投与後経時的にＸ線撮影
による検査を行なったところ、被検者の消化管の、運動
状態が把握され、投与された硫酸バリウム顆粒はそのま
まの形状を保ったまま***された。After administration of 2 g of this granule, an examination by X-ray photography was carried out over time. As a result, the motility state of the digestive tract of the subject was ascertained, and the administered barium sulfate granules kept their original shape. It was excreted as it was.
【００１９】[0019]
【発明の効果】本発明の製剤を使用することによって被
検者の消化管の運動機能の検査を行なうことができる。EFFECT OF THE INVENTION By using the preparation of the present invention, it is possible to test the motor function of the digestive tract of a subject.
【００２０】なお、この製剤は、数種の形状を作り、経
時的連続投与をすることにより、さらに高度の検査も可
能である。Further, this preparation can be subjected to a higher degree of examination by making several kinds of shapes and continuously administering it over time.
Claims (1)
ルセルロースが使用されている硫酸バリウム粒状製剤1. Barium sulphate granular preparation in which ethyl cellulose is used as binder or coating agent
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7016741A JPH08208527A (en) | 1995-02-03 | 1995-02-03 | Particular barium sulfate preparation for internal use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7016741A JPH08208527A (en) | 1995-02-03 | 1995-02-03 | Particular barium sulfate preparation for internal use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08208527A true JPH08208527A (en) | 1996-08-13 |
Family
ID=11924700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7016741A Pending JPH08208527A (en) | 1995-02-03 | 1995-02-03 | Particular barium sulfate preparation for internal use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH08208527A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015000870A (en) * | 2013-06-18 | 2015-01-05 | ニュートリー株式会社 | Food for videofluorgraptic examination of swallowing |
-
1995
- 1995-02-03 JP JP7016741A patent/JPH08208527A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015000870A (en) * | 2013-06-18 | 2015-01-05 | ニュートリー株式会社 | Food for videofluorgraptic examination of swallowing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9907816B2 (en) | Water-insoluble, iron-containing mixed metal, granular material | |
| US5211958A (en) | Pharmaceutical composition and process for its preparation | |
| JPH0688905B2 (en) | Solid pharmaceutical preparation for oral administration containing erythromycin derivative and method for producing the same | |
| EP2897594B1 (en) | Pharmaceutical composition | |
| EA003161B1 (en) | Method for manufacturing coated granules with masked taste and instant release of the active principle | |
| Phutane et al. | In vitro evaluation of novel sustained release microspheres of glipizide prepared by the emulsion solvent diffusion-evaporation method | |
| Dinu et al. | The antibiotic vancomycin induces complexation and aggregation of gastrointestinal and submaxillary mucins | |
| JP2609022B2 (en) | Polycarbophil calcium-containing preparation | |
| CN101563295A (en) | Iron (III)-carbohydrate based phosphate adsorbent | |
| US5589191A (en) | Slow-release sodium valproate tablets | |
| JPH0717866A (en) | Medicinal composition | |
| Upadhyay et al. | Natural polymers composed mucoadhesive interpenetrating buoyant hydrogel beads of capecitabine: Development, characterization and in vivo scintigraphy | |
| CN1215342A (en) | Contrast medium | |
| JPH08208527A (en) | Particular barium sulfate preparation for internal use | |
| WO2007092784A1 (en) | Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates | |
| CA2028633A1 (en) | Sustained-release preparation of basic medical agent hydrochloride | |
| Kurrey et al. | Hollow microspheres as a drug carrier: An overview of fabrication and in vivo characterization techniques | |
| EP0669135A1 (en) | Granular preparation for mri | |
| JPH08157393A (en) | Barium sulfate granular preparation for internal use | |
| Krishna et al. | Strategic Approaches and Evaluation of Gastro Retentive Drug Delivery system-A Review | |
| JP3592723B2 (en) | Non-disintegrating and sustained capsule formulation | |
| US2676902A (en) | Para-aminosalicylic acid containing compositions | |
| CA1135619A (en) | Solution of sodium iomorinate for use in peroral rapid cholecystography | |
| CN112022827B (en) | Cyproheptadine hydrochloride quick-release pharmaceutical preparation and preparation method thereof | |
| Pundlikrao et al. | Use of black gram polysaccharide mucilage as release retardant in the development of sustained release matrix pellets of ciprofloxacin hydrochloride |